These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 26695512)

  • 1. A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.
    Bisacchi GS; Hale MR
    Curr Med Chem; 2016; 23(6):520-77. PubMed ID: 26695512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advancements in the medicinal chemistry of bacterial type II topoisomerase inhibitors.
    Jaswal S; Nehra B; Kumar S; Monga V
    Bioorg Chem; 2020 Nov; 104():104266. PubMed ID: 33142421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
    Kassab AE; Gedawy EM
    Eur J Med Chem; 2018 Apr; 150():403-418. PubMed ID: 29547830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The quinolone family: from antibacterial to anticancer agents.
    Sissi C; Palumbo M
    Curr Med Chem Anticancer Agents; 2003 Nov; 3(6):439-50. PubMed ID: 14529452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity.
    Naeem A; Badshah SL; Muska M; Ahmad N; Khan K
    Molecules; 2016 Mar; 21(4):268. PubMed ID: 27043501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
    Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
    Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.
    Aldred KJ; Schwanz HA; Li G; McPherson SA; Turnbough CL; Kerns RJ; Osheroff N
    ACS Chem Biol; 2013 Dec; 8(12):2660-8. PubMed ID: 24047414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.
    Pommier Y; Leo E; Zhang H; Marchand C
    Chem Biol; 2010 May; 17(5):421-33. PubMed ID: 20534341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards anticancer fluoroquinolones: A review article.
    Abdel-Aal MAA; Abdel-Aziz SA; Shaykoon MSA; Abuo-Rahma GEA
    Arch Pharm (Weinheim); 2019 Jul; 352(7):e1800376. PubMed ID: 31215674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functionalized N(2-oxyiminoethyl) piperazinyl quinolones as new cytotoxic agents.
    Rajabalian S; Foroumadi A; Shafiee A; Emami S
    J Pharm Pharm Sci; 2007; 10(2):153-8. PubMed ID: 17706174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Novel Topoisomerase II Inhibitors by Medicinal Chemistry Approaches.
    Hu W; Huang XS; Wu JF; Yang L; Zheng YT; Shen YM; Li ZY; Li X
    J Med Chem; 2018 Oct; 61(20):8947-8980. PubMed ID: 29870668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of 2-phenol-4-chlorophenyl-6-aryl pyridines as topoisomerase II inhibitors and cytotoxic agents.
    Thapa P; Kadayat TM; Park S; Shin S; Thapa Magar TB; Bist G; Shrestha A; Na Y; Kwon Y; Lee ES
    Bioorg Chem; 2016 Jun; 66():145-59. PubMed ID: 27174797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases.
    Singh S; Pandey VP; Yadav K; Yadav A; Dwivedi UN
    Curr Protein Pept Sci; 2020; 21(11):1103-1142. PubMed ID: 32951576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of 3,5-substituted 1,2,4-oxadiazoles as catalytic inhibitors of human DNA topoisomerase IIα.
    Loboda KB; Valjavec K; Štampar M; Wolber G; Žegura B; Filipič M; Dolenc MS; Perdih A
    Bioorg Chem; 2020 Jun; 99():103828. PubMed ID: 32315896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topoisomerase IV is a target of quinolones in Escherichia coli.
    Khodursky AB; Zechiedrich EL; Cozzarelli NR
    Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11801-5. PubMed ID: 8524852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast.
    Elsea SH; Osheroff N; Nitiss JL
    J Biol Chem; 1992 Jul; 267(19):13150-3. PubMed ID: 1320012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
    My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ
    Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the discovery and development of quinolones and analogs as antitumor agents.
    Xia Y; Yang ZY; Morris-Natschke SL; Lee KH
    Curr Med Chem; 1999 Mar; 6(3):179-94. PubMed ID: 10219099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers.
    Abbass EM; Khalil AK; Mohamed MM; Eissa IH; El-Naggar AM
    Bioorg Chem; 2020 Nov; 104():104255. PubMed ID: 32927130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors.
    Yao BL; Mai YW; Chen SB; Xie HT; Yao PF; Ou TM; Tan JH; Wang HG; Li D; Huang SL; Gu LQ; Huang ZS
    Eur J Med Chem; 2015 Mar; 92():540-53. PubMed ID: 25599951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.